Shares of Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) dropped 4.7% during trading on Monday . The company traded as low as $4.77 and last traded at $4.77. Approximately 1,050 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 299,064 shares. The stock had previously closed at $5.00.
Innovent Biologics Stock Down 0.2 %
The business has a 50 day moving average of $4.84 and a 200 day moving average of $5.16.
About Innovent Biologics
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Read More
- Five stocks we like better than Innovent Biologics
- How to Use the MarketBeat Excel Dividend Calculator
- Best Bear Market Funds: Top 3 Investment Options to Consider
- How to Evaluate a Stock Before BuyingÂ
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
